PROK2 and Parkinson disease: Combined with the above-mentioned observation that blocking PK2 signalling in vivo potentiates MPTP toxicity, these results convincingly demonstrate a protective role for PK2 signalling in the nigrostriatal dopaminergic system and suggest that modulating PK2 levels may be a novel therapeutic strategy for PD.